Compare Gilead Sciences, Inc. (GILD) vs QUALCOMM, Inc. (QCOM) Price & Performance

Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.

The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.

Qualcomm (QCOM) trades at $178.08, down 3.21% today, amid a bearish technical signal and mixed sentiment. Recent earnings have consistently beaten estimates, with Q1 2026 EPS of $2.65 surpassing the $2.56 forecast. The company maintains strong profitability with a 54.8% gross margin and 22.31% net income margin, while diversifying into AI and automotive markets. News highlights Nvidia's entry into the PC chip market increasing competitive pressures.

The outlook is cautiously optimistic with a consensus price target of $222.53 implying 25% upside, but near-term risks include smartphone demand softness and margin pressures. Long-term growth hinges on successful expansion in AI and data centers, though competition and market volatility pose challenges to shareholder returns.